HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $10 price target.
‘Oklahoma House Approves Psilocybin Bill Protecting Patients From Prosecution And Promoting Research’ – Marijuana Moment
https://www.marijuanamoment.net/oklahoma-house-approves-psilocybin-bill-protecting-patients-from-prosecution-and-promoting-research/
The Oklahoma House of Representatives has approved a bill to promote research into the
‘Hawaii Senate Approves Marijuana Legalization And Psychedelic Research Bills’ – Marijuana Moment
https://www.marijuanamoment.net/hawaii-senate-approves-marijuana-legalization-and-psychedelic-research-bills/
Psyched: 9 US Reform Bills, Ayahuasca ‘A Release’ For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization
Throughout the 2023 session, numerous discussions have been held and various measures have been considered around the legalization of psychedelics.
Let’s go over the latest proposed regulations.
Cybin: Positive Clinical Trial On Psilocybin Analog For Major Depression & Updates On DMT Analog Program
Psychedelics biotech company Cybin Inc.
Psyched: Hawaii And Minnesota’s Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry’s Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement
Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and psilocybin as an alternative to treat mental health conditions.
Cybin Restructures Staff As It Enters Clinical-Stage Era: Here’s How The Market Responded
Cybin Inc. (NEO:CYBN) (AMEX:CYBN) announced Thursday a streamlining plan aimed at maximizing the company’s operating efficiency and allowing it to focus on critical clinical trials.
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback
Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while some of the already filed ones continue progressing and others get a thumbs down.
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022.
The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15 million as of Feb. 14, 2023.
EF Hutton Reiterates Buy on Cybin, Maintains $3 Price Target
EF Hutton analyst Elemer Piros reiterates Cybin (AMEX:CYBN) with a Buy and maintains $3 price target.